Platform to discover and develop molecular glues

TRIANA Biomedicines is pioneering a transformative approach in drug discovery through the development of molecular glues, which are small molecules designed to promote interactions between proteins. This innovative technology enables the formation of ternary complexes by "gluing" two proteins together, thereby altering the function or fate of disease target proteins. A significant application of this technology is in targeted protein degradation (TPD), where TRIANA aims to activate the cell's innate protein degradation machinery to eliminate disease-causing proteins. By focusing on challenging disease targets that have traditionally been considered undruggable, TRIANA's approach opens new avenues for treating various diseases, particularly cancer.

The company's drug discovery engine is bolstered by high-resolution structural insights, advanced AI and computational tools, and customized chemical libraries. TRIANA employs a target-first and rational strategy to identify E3 ligases that can be matched with disease targets, facilitating the discovery of new molecular glues. This comprehensive glue discovery campaign aims to explore diverse chemical spaces, ultimately leading to the development of groundbreaking therapeutics that can significantly improve patient outcomes. By leveraging these cutting-edge technologies, TRIANA Biomedicines is positioned to fundamentally change the landscape of small molecule drug discovery.

United States

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed.

TRIANA Biomedicines

Company Details